clinical trial · NCT04259086
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
Revance Therapeutics, Inc.·phase2·completed·n = 48
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)DaxibotulinumtoxinA for injection
brief summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
started
Dec 6, 2019
primary completion
Nov 2, 2020
completion
Nov 2, 2020
last updated
Jun 27, 2023
official title
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol